Archive for the Category ◊ Vascular/ Cardiovascular ◊

• Wednesday, June 17th, 2015

TriVascular Technologies, Inc. Announces FDA Approval of Ovation iX(TM) Iliac Stent Graft  SANTA ROSA, Calif., June 15, 2015 (GLOBE NEWSWIRE) — TriVascular Technologies, Inc. (Nasdaq:TRIV) announced today that the U.S. Food and Drug Administration (FDA) has approved the Ovation iX Iliac Stent Graft for the Ovation Prime® Abdominal Stent Graft System, together with manufacturing enhancements […]

• Tuesday, February 17th, 2015

Like many big health care companies, Medtronic PLC has taken on a lot of additional debt in a bid to transform itself into the medical device company of the future. But a new analysis shows the strategy comes with risks. Carrying high debt leaves merging companies a thin cushion to absorb setbacks like litigation or unexpected integration […]

• Tuesday, February 17th, 2015

Stabbed five times, Claudio Cara lay dying on the kitchen floor of his Oshawa home. The final thrust of the knife — one Cara preferred for slicing Italian sweets — was likely the fatal one. The blade protruded from the 56-year-old’s chest, the handle missing. The business of estimating exact time of death is inaccurate. […]

• Friday, July 25th, 2014

St. Jude Medical Inc. will lay off up to 270 employees at its Sylmar heart-device manufacturing facility following a corporate restructuring. The St. Paul, Minn. medical device company said it is eliminating the second shift at the Sylmar plant to optimize operations. That facility produces implantable defibrillators and pacemaker products. The layoffs are scheduled to […]

• Friday, February 14th, 2014

Medtronic Launches ‘TOTAL Across’ Crossing Catheter in Europe  MINNEAPOLIS — Feb. 13, 2014 — Aligned with its commitment to provide innovative medical technology for the interventional treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) has initiated the European launch of the TOTAL across crossing catheter, which recently received the CE (Conformité Européene) mark as […]

• Thursday, February 13th, 2014

The Vanguard Group buys a big stake in Boston Scientific as BlackRock expands its holdings in the medical device company. Count mutual fund giant Vanguard Group and hedge fund BlackRock Inc. among the believers in the comeback story at Boston Scientific (NYSE:BSX). Vanguard took up a 6.7% stake in Boston Scientific as of the end of last […]

• Tuesday, February 04th, 2014

Bard Announces $500 Million Share Repurchase Authorization MURRAY HILL, N.J.–(BUSINESS WIRE)–C. R. Bard, Inc. (NYSE:BCR) today announced that its Board of Directors has authorized the repurchase of up to $500 million of the company’s common stock. This new authorization is in addition to the approximately $55 million remaining under the Company’s prior authorization. Share repurchases […]

• Wednesday, January 29th, 2014

Negative Pressure Wound Therapy helps reduce infections and other surgical complications, according to a clinical review published by a Smith & Nephew-funded expert panel. Smith & Nephew (FTSE:SN, NYSE:SNN) touted the outcomes of a clinical study review, reporting that Negative Pressure Wound Therapy proved effective in reducing complications when applied to surgical wounds for a few […]

• Tuesday, January 21st, 2014

St. Jude Medical quietly accepts FDA premarket approval for its Cool Flex ablation catheter and ablation generator for treatment of arrhythmia. Medtech titan St. Jude Medical (NYSE:STJ) won FDA premarket approval for its Cool Flex cardiac ablation system with indication to treat irregular heart rhythms. St. Jude accepted the win quietly, with not announcements listed on its site […]

• Tuesday, January 21st, 2014

Boston Scientific Corp. (BSX) won’t begin a study of its hypertension treatment until it can analyze a failed effort by Medtronic Inc. (MDT) and review its approach with U.S. regulators, Chief Executive Officer Michael Mahoney said. While Boston Scientific has Food and Drug Administration backing to start a pivotal trial of its Vessix technology, the company is waiting […]